6lc9

Crystal structure of AmpC Ent385 complex form with ceftazidime

spinqualitylabelsall models 6lc9, resolution 1.65Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 6lc9 is a 2 chain structure with sequence from "aerobacter_cloacae"_(jordan_1890)_bergey_et_al._1923 "aerobacter cloacae" (jordan 1890) bergey et al. 1923. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Ligands: CAZ, DIO, GOL, SO4 Gene: CKO00_24250 ("Aerobacter cloacae" (Jordan 1890) Bergey et al. 1923) Activity: Beta-lactamase, with EC number 3.5.2.6 Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Publication Abstract from PubMed Ceftazidime-avibactam and cefiderocol are two of the latest generation beta-lactam agents that possess expanded activity against highly drug-resistant bacteria, including carbapenem-resistant Enterobacterales Here we show that structural changes in AmpC beta-lactamases can confer reduced susceptibility to both agents. A multidrug-resistant Enterobacter cloacae clinical strain (Ent385) was found to be resistant to ceftazidime-avibactam and cefiderocol without prior exposure to either agent. The AmpC beta-lactamase of Ent385 (AmpC(Ent385)) contained an alanine-proline deletion at positions 294-295 (A294_P295del) in the R2 loop. AmpC(Ent385) conferred reduced susceptibility to ceftazidime-avibactam and cefiderocol when cloned into Escherichia coli TOP10. Purified AmpC(Ent385) showed increased hydrolysis of ceftazidime and cefiderocol compared with AmpC(Ent385Rev), in which the deletion was reverted. Comparisons of crystal structures of AmpC(Ent385) and AmpC(P99), the canonical AmpC of E. cloacae, revealed that the two-residue deletion in AmpC(Ent385) induced drastic structural changes of the H-9 and H-10 helices and the R2 loop, which accounted for the increased hydrolysis of ceftazidime and cefiderocol. The potential for a single mutation in ampC to confer reduced susceptibility to both ceftazidime-avibactam and cefiderocol requires close monitoring.Importance Ceftazidime-avibactam and cefiderocol are newly approved beta-lactam agents that possess broad spectrum activity against multidrug-resistant (MDR) Gram-negative bacteria. We show here that a two amino-acid deletion in the chromosomal AmpC beta-lactamase, identified in a clinical strain of Enterobacter cloacae, confers reduced susceptibility to both agents. By crystallographic studies of free and drug-bound forms of enzyme, we demonstrate that this deletion in AmpC induces slanting of the H-9 helix that is directly connected with the R2 loop, and disappearance of the H-10 helix, is directly responsible for increased hydrolysis of ceftazidime and cefiderocol. These findings provide novel insights into how MDR Gram-negative bacteria may evolve their beta-lactamases to survive selective pressure from these newly developed beta-lactam agents. Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion.,Kawai A, McElheny CL, Iovleva A, Kline EG, Sluis-Cremer N, Shields RK, Doi Y Antimicrob Agents Chemother. 2020 Apr 13. pii: AAC.00198-20. doi:, 10.1128/AAC.00198-20. PMID:32284381 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See Also Beta-lactamase 3D structures

Proteopedia Page Contributors and Editors (what is this?)

OCA